Regorafenib in patients with recurrent high-grade astrocytoma
| Autor: | Teresa Schmidt, Christoph Kleinschnitz, Daniela Pierscianek, Lazaros Lazaridis, Kathy Keyvani, Björn Scheffler, Ulrich Sure, Martin Glas, Alexander Radbruch, Laurèl Rauschenbach, Martin Stuschke, Ann-Kathrin Stoppek, Michael Forsting, Sied Kebir |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology Cancer Research medicine.medical_specialty Adolescent Pyridines Medizin Angiogenesis Inhibitors Astrocytoma law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Internal medicine Regorafenib medicine Humans Adverse effect Aged Retrospective Studies Hematology Brain Neoplasms business.industry Phenylurea Compounds Retrospective cohort study General Medicine Middle Aged medicine.disease Progression-Free Survival 030104 developmental biology chemistry 030220 oncology & carcinogenesis Toxicity Female Neoplasm Grading business Progressive disease |
| Popis: | Antiangiogenic treatment approaches have failed to improve outcome in randomized trials of high-grade astrocytoma. One key mechanism of resistance to antiangiogenic treatment may concern the upregulation of alternative pro-angiogenic pathways. Regorafenib is a potent multikinase inhibitor that may alter some of those pathways. In this retrospective study, we investigated efficacy and radiographic tumor growth patterns of regorafenib in recurrent high-grade astrocytoma. We screened for patients with high-grade astrocytoma in whom regorafenib was administered for at least 4 weeks. We assessed treatment efficacy in terms of progression-free survival (PFS), overall survival, and adverse events defined by Common Toxicity Criteria (CTC). In addition, radiographic tumor growth patterns were determined at baseline and recurrence. A total of 6 patients met eligibility criteria. The number of recurrences prior to regorafenib varied between 2 and 6. Patients were on regorafenib treatment for at least 4 weeks and maximally 14 weeks. Median PFS was 3.5 months and ranged from 2.0 to 4.0 months. Radiographic response was progressive disease in all patients with an objective response rate of 0%. CTC°3 adverse events were observed in all but one patient. The most common radiographic growth pattern was local with no change in growth pattern at recurrence. An infiltrative tumor growth was not induced in any patient. This retrospective study indicates a very poor performance of regorafenib in recurrent high-grade astrocytoma with a fairly high number of CTC°3 adverse events. In addition, regorafenib does not seem to bear a potential for infiltrative tumor growth promotion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|